The estimated Net Worth of Management Pte Ltd Temasek ... is at least $119 Millón dollars as of 9 December 2015. Management Temasek owns over 750,000 units of Portola Pharmaceuticals stock worth over $118,701,731 and over the last 9 years Management sold PTLA stock worth over $0.
Management has made over 2 trades of the Portola Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Management bought 750,000 units of PTLA stock worth $36,000,000 on 9 December 2015.
The largest trade Management's ever made was buying 750,000 units of Portola Pharmaceuticals stock on 9 December 2015 worth over $36,000,000. On average, Management trades about 750,000 units every 0 days since 2015. As of 9 December 2015 Management still owns at least 6,583,568 units of Portola Pharmaceuticals stock.
You can see the complete history of Management Temasek stock trades at the bottom of the page.
Over the last 16 years, insiders at Portola Pharmaceuticals have traded over $63,947,373 worth of Portola Pharmaceuticals stock and bought 4,311,442 units worth $137,660,828 . The most active insiders traders include (Mauritius) Pte Ltd Cairnhi..., James N Topper y Jeffrey W Bird. On average, Portola Pharmaceuticals executives and independent directors trade stock every 43 days with the average trade being worth of $1,543,350. The most recent stock trade was executed by Hollings Renton on 1 November 2019, trading 5,000 units of PTLA stock currently worth $45,000.
Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.
Portola Pharmaceuticals executives and other stock owners filed with the SEC include: